Bacterin International Holdings (BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries. Bacterin's Medical Device division develops, employs and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination.
(click to enlarge)
Insider buys
Guy Cook purchased 5,000 shares on September 11 and 95,451 shares during May 9 - June 8 period. Guy Cook owns 25.2% of the company. Guy Cook serves as a Chairman of the board, CEO and President of the company.
Kent Swanson purchased 27,977 shares on June 11 and currently controls 450,000 shares of the company. Kent Swanson serves as a Director and Compensation Committee Chairman.
Jon Wickwire purchased 20,000 shares on May 8 and currently controls 363,139 shares of the company. Jon Wickwire serves as a Director and Chairman of Corporate Governance and Nominating Committees.
http://seekingalpha.com/article/885411-5-healthcare-companies-with-insider-buying-during-september-2012?source=yahoo
http://www.secform4.com/insider-trading/1453593.htm
(click to enlarge)
Insider buys
Guy Cook purchased 5,000 shares on September 11 and 95,451 shares during May 9 - June 8 period. Guy Cook owns 25.2% of the company. Guy Cook serves as a Chairman of the board, CEO and President of the company.
Kent Swanson purchased 27,977 shares on June 11 and currently controls 450,000 shares of the company. Kent Swanson serves as a Director and Compensation Committee Chairman.
Jon Wickwire purchased 20,000 shares on May 8 and currently controls 363,139 shares of the company. Jon Wickwire serves as a Director and Chairman of Corporate Governance and Nominating Committees.
http://seekingalpha.com/article/885411-5-healthcare-companies-with-insider-buying-during-september-2012?source=yahoo
http://www.secform4.com/insider-trading/1453593.htm
Recent XTNT News
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/29/2026 08:05:06 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/13/2026 11:33:08 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 11:15:38 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 11:05:34 AM
- Xtant Medical Reports First Quarter 2026 Financial Results • PR Newswire (US) • 05/13/2026 11:00:00 AM
- Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026 • PR Newswire (US) • 05/07/2026 12:00:00 PM
- Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped • PR Newswire (US) • 05/06/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 01:20:24 PM
- Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product • PR Newswire (US) • 04/13/2026 01:04:00 PM
- Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial • PR Newswire (US) • 04/09/2026 12:00:00 PM
- Xtant Medical shares drop nearly 5% as weak 2026 outlook overshadows Q4 beat • IH Market News • 03/31/2026 02:54:42 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 11:16:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:05:23 AM
- Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results • PR Newswire (US) • 03/31/2026 11:00:00 AM
- Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026 • PR Newswire (US) • 03/25/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 01:15:49 PM
- Xtant Medical Finalizes Companion Spine Transactions • PR Newswire (US) • 03/02/2026 01:00:00 PM
- Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference • PR Newswire (US) • 02/25/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 10:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2026 09:15:32 PM
- Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft • PR Newswire (US) • 12/11/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2025 09:05:52 PM

